The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

Documenti analoghi

• Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
  di: Quintás-Cardama, Alfonso, et al.
  Pubblicazione: (2009)
• Prognostic Impact of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia Treated With Nilotinib or Dasatinib
  di: Quintás-Cardama, Alfonso, et al.
  Pubblicazione: (2011)
• The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
  di: Jabbour, Elias, et al.
  Pubblicazione: (2011)
• EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
  di: Jabbour, Elias, et al.
  Pubblicazione: (2012)
• Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
  di: Tam, Constantine S., et al.
  Pubblicazione: (2008)